4-(2-氨基乙基)苯-1,3-二醇 | 2039-62-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(2-氨基乙基)苯-1,3-二醇
• 英文名称: 2,4-dihydroxyphenylethylamine
• 英文别名: 3-hydroxytyramine；2,4-Dihydroxy-phenaethylamin；4-(2-Aminoethyl)benzene-1,3-diol
• CAS: 2039-62-5
• 化学式: C₈H₁₁NO₂
• 分子量: 153.181
• InChiKey: URFGSZVXJZMYHZ-UHFFFAOYSA-N

物化性质

• 沸点：
  338.2±11.0 °C(Predicted)
• 密度：
  1.247±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  66.5
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-氨基乙基)苯-1,3-二醇 、 联苯-3-羧酸肼 在 potassium hydroxide 作用下， 以 乙醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-([1,1‘-biphenyl]-3-yl)-4-[2-(2,4-dihydroxyphenyl)ethyl]-2,4-dihydro-1,2,4-triazole-3-thione
  参考文献：
  名称：

  1,2,4-三唑-3-硫酮类似物，在第 4 位具有芳烷基作为金属-β-内酰胺酶抑制剂

  摘要：

  金属-β-内酰胺酶 (MBL) 对公众健康构成越来越严重的威胁，因为它们在全球范围内在相关机会性革兰氏阴性病原体中的流行率增加。MBL 可有效灭活广泛使用且最有价值的 β-内酰胺类抗生素，例如氧亚氨基头孢菌素（头孢曲松、头孢他啶）和最后的碳青霉烯类。迄今为止，还没有 MBL 抑制剂被批准用于治疗应用。我们正在开发以 1,2,4-三唑-3-硫酮支架为原始锌配体特征的抑制剂，并且已经报道了一些有前途的系列。在这里，我们介绍了一系列新化合物的合成和评估，这些化合物的特征是在三唑环的 4 位存在芳基烷基取代基。烷基链主要是乙烯，但也合成了一些不含烷基或具有不同长度的烷基（直至丁基链）的化合物。两个子系列中的一些化合物是测试的 VIM 型 MBL 的微摩尔到亚微摩尔抑制剂。其中一些是广谱抑制剂，因为它们对 NDM-1 和 IMP-1 表现出显着的抑制活性。其中，几种抑制剂能够将美罗培南对产生 VIM-1

  DOI：

  10.1016/j.bmc.2022.116964
• 作为产物：
  描述：

  2,4-dihydroxy-L-phenylalanine 在 NH₄OH-NH₄Cl buffer 、 磷酸吡哆醛 作用下， 反应 0.5h， 生成 4-(2-氨基乙基)苯-1,3-二醇
  参考文献：
  名称：

  Nakazawa, Hidetsugu; Kumagai, Hidehiko; Yamada, Hideaki, Agricultural and Biological Chemistry, 1981, vol. 45, # 11, p. 2543 - 2552

  摘要：

  DOI：

文献信息

• [EN] ASPARAGINE DERIVATIVES AND METHODS OF USING SAME<br/>[FR] DÉRIVÉS D'ASPARAGINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：SENDA BIOSCIENCES INC

  公开号：WO2021252640A1

  公开（公告）日：2021-12-16

  The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, intermediate compounds useful for preparing the same, and methods for treating or prophylaxis of diseases, in particular cancer, such as colorectal cancer, using the same.

  本公开涉及式（A）和（I）的化合物，其药学上可接受的盐，以及任何上述化合物的溶剂化合物，包括相同的药物组合物，制备相同的方法，用于制备相同的中间化合物，以及使用相同的方法治疗或预防疾病，特别是癌症，如结直肠癌。
• Benzopyran Compound
  申请人：Tsukagoshi Toru

  公开号：US20070299130A1

  公开（公告）日：2007-12-27

  This invention relates to benzopyran compounds of formula (I) wherein X is NR 6 , Y is a bond, SO or SO 2 , Z is C 1-4 alkyl group or phenyl group, W is hydrogen atom, hydroxy group, C 1-6 alkoxy group, a halogen atom, C 1-4 alkyl group or C 1-6 alkylsulfonylamino group, R 1 and R 2 are independently of each other C 1-3 alkyl group, R 3 is hydrogen atom, hydroxy group or methoxy group, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR 7 R 8 , NR 9 , O, S, SO or SO 2 , R 4 is hydrogen atom or C 1-6 alkyl group, R 5 is hydrogen atom, C 1-6 alkyl group, C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, C 6-14 aryl group or C 2-9 heteroaryl group. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及式（I）的苯并吡喃化合物，其中X为NR6，Y为键，SO或SO2，Z为C1-4烷基或苯基，W为氢原子，羟基，C1-6烷氧基，卤素原子，C1-4烷基或C1-6烷基磺酰氨基，R1和R2分别为C1-3烷基，R3为氢原子，羟基或甲氧基，m为0至4的整数，n为0至4的整数，V为单键，CR7R8，NR9，O，S，SO或SO2，R4为氢原子或C1-6烷基，R5为氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，C6-14芳基或C2-9杂芳基。这些化合物可用作抗心律失常剂。
• Tricyclic Benzopyrane Compound as Anti-Arrhythmic Agents
  申请人：Ohrai Kazuhiko

  公开号：US20080004262A1

  公开（公告）日：2008-01-03

  This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R 1 and R 2 are independently of each other hydrogen atom, C 1-6 alkyl group or C 6-14 aryl group, R 3 is hydrogen atom or C 1-6 alkylcarbonyloxy group, or together with R 4 forms a bond, R 4 is hydrogen atom, or together with R 3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR 7 R 8 , NR 9 , O, S, SO or SO 2 , R 5 is hydrogen atom or C 1-6 alkyl group, R 6 is hydrogen atom, C 1-6 alkyl group, C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, amino group, C 1-6 alkylamino group, di-C 1-6 alkylamino group, C 6-14 arylamino group, C 2-9 heteroarylamino group, C 6-14 aryl group, C 2-9 heteroaryl group or C 2-9 heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及式（I）或（II）的苯并吡喃衍生物，或其药学上可接受的盐，其中R1和R2独立地为氢原子，C1-6烷基或C6-14芳基；R3为氢原子或C1-6烷基羰氧基，或与R4一起形成键；R4为氢原子，或与R3一起形成键；m为0至4的整数，n为0至4的整数，V为单键，CR7R8，NR9，O，S，SO或SO2；R5为氢原子或C1-6烷基，R6为氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，氨基，C1-6烷基氨基，二C1-6烷基氨基，C6-14芳基氨基，C2-9杂芳基氨基，C6-14芳基，C2-9杂芳基或C2-9杂环烷基；A为与苯环融合的5、6或7元环，作为环的组成原子，其中单独或组合存在1至3个氧原子、氮原子或硫原子，环中不饱和键的数量为1、2或3，包括与苯环融合的不饱和键，构成环的碳原子可以是羰基或硫代羰基。这些化合物可用作抗心律失常药物。
• Tricyclic benzopyrane compound
  申请人：Ohrai Kazuhiko

  公开号：US20100069374A1

  公开（公告）日：2010-03-18

  This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R 1 and R 2 are independently of each other hydrogen atom, C 1-6 alkyl group or C 6-14 aryl group, R 3 is hydrogen atom or C 1-6 alkylcarbonyloxy group, or together with R 4 forms a bond, R 4 is hydrogen atom, or together with R 3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR 7 R 8 , NR 9 , O, S, SO or SO 2 , R 5 is hydrogen atom or C 1-6 alkyl group, R 6 is hydrogen atom, C 1-6 alkyl group, C 3-8 cycloalkyl group, C 3-8 cycloalkenyl group, amino group, C 1-6 alkylamino group, di-C 1-6 alkylamino group, C 6-14 arylamino group, C 2-9 heteroarylamino group, C 6-14 aryl group, C 2-9 heteroaryl group or C 2-9 heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及公式（I）或（II）的苯并吡喃衍生物或其药学上可接受的盐， 其中R1和R2独立地是氢原子，C1-6烷基或C6-14芳基，R3是氢原子或C1-6烷基羰氧基，或与R4一起形成键，R4是氢原子，或与R3一起形成键，m是0到4的整数，n是0到4的整数，V是单键，CR7R8，NR9，O，S，SO或SO2，R5是氢原子或C1-6烷基，R6是氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，氨基，C1-6烷基氨基，双C1-6烷基氨基，C6-14芳基氨基，C2-9杂芳基氨基，C6-14芳基，C2-9杂芳基或C2-9杂环烷基，A是与苯环融合的5、6或7成员环，作为环的组成原子，其中含有1到3个氧原子，氮原子或硫原子，或其组合，环中不饱和键的数量为1、2或3，包括与苯环融合的不饱和键，构成环的碳原子可以是羰基或硫代羰基。这些化合物可用作抗心律失常剂。
• N-substituted oligomers and methods for their synthesis, e.g. polyglycine bearing nucleic acid bases
  申请人：CHIRON CORPORATION

  公开号：EP1258492A1

  公开（公告）日：2002-11-20

  Poly N-substituted Glycines (poly NSGs), wherein the substituents bear purine or pyrimidine bases (R9) every second glycine: In addition, a solid phase method for the synthesis of N-substituted oligomers of more general structures is disclosed.The poly NSGs obtainable by this method can have a wide variety of side-chain substituents. Each N-substituted glycine monomer is assembled from two "sub-monomers" directly on the solid support. Each cycle of monomer addition consists of two steps: (1) acylation of a secondary amine bound to the support with an acylating agent comprising a leaving group capable of nucleophilic displacement by -NH2, such as a haloacetic acid, and (2) introduction of the side-chain by nucleophilic displacement of the leaving group, such as halogen (as a resin-bound α-haloacetamide) with a sufficient amount of a second sub-monomer comprising an -NH2 group, such as a primary amine, alkoxyamine, semicarbazide, acyl hydrazide, carbazate or the like. Repetition of the two step cycle of acylation and displacement gives the desired oligomers. The efficient synthesis of a wide variety of oligomeric NSGs using the automated synthesis technology of the present method makes these oligomers attractive candidates for the generation and rapid screening of diverse peptidomimetic libraries. The oligomers of the invention, such as N-substituted glycines (i.e. poly NSGs) disclosed here provide a new class of peptide-like compounds not found in nature, but which are synthetically accessible and have been shown to possess significant biological activity and proteolytic stability.

  聚 N-取代甘氨酸（poly NSGs），其中每第二个甘氨酸的取代基都带有嘌呤或嘧啶碱（R9）： 此外，还公开了一种用于合成更一般结构的 N-取代低聚物的固相方法。通过这种方法获得的聚 NSG 可以具有多种侧链取代基。每个 N-取代甘氨酸单体由两个 "子单体 "直接在固体支持物上组装而成。每个单体加成循环包括两个步骤：(1) 用包含能被 -NH2 亲核置换的离去基团（如卤乙酸）的酰化剂将与载体结合的仲胺酰化，以及 (2) 通过离去基团的亲核置换引入侧链、(2) 通过亲核置换离去基团，如卤素（作为与树脂结合的 α-卤代乙酰胺）和足量的包含 -NH2 基团的第二亚单体，如伯胺、烷氧基胺、半肼、酰肼、肼基脲或类似物，引入侧链。重复酰化和置换两步循环，即可得到所需的低聚物。利用本方法的自动合成技术可高效合成多种低聚 NSG，这使得这些低聚物在生成和快速筛选各种肽模拟库方面具有吸引力。本发明公开的低聚物，如 N-取代甘氨酸（即多 NSG），提供了一类新的肽类化合物，这类化合物在自然界中并不存在，但可以通过合成获得，而且已被证明具有显著的生物活性和蛋白水解稳定性。